---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-035174"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:52:25.219979+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics FY2025 net loss $20.2M ($0.61/sh); cash $20.8M; Phase 1b data supports GT-02287

## Summary
- Net loss $20.2M ($0.61 per share) vs $20.4M ($0.89) prior year; R&D $10.2M, G&A $8.5M.
- Cash, equivalents & marketable securities $20.8M as of Dec 31, 2025 (up from $10.4M).
- Phase 1b extension: 14 of 16 participants completed day 150; MDS-UPDRS scores stable.
- CSF GluSph decreased 81% at day 90 in elevated-baseline participants; DDC also reduced.
- IND submission for GT-02287 expected 2Q26; Phase 2 start 3Q26; Phase 1b final data 4Q26.

## SEC filing metadata
- accession: 0001104659-26-035174
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465926035174/0001104659-26-035174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465926035174/ganx-20260326x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-035174
- JSON: https://secwatch.observer/filing/0001104659-26-035174.json
- Plain text: https://secwatch.observer/filing/0001104659-26-035174.txt

## Key facts
- Earnings Releases
  Gain Therapeutics, Inc. reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $20.2 million, or $0.61 per share, basic and diluted, EPS $0.61 per share, basic and diluted.
  - Period: year ended December 31, 2025
  - Net income: Net loss for the year ended December 31, 2025, was $20.2 million, or $0.61 per share, basic and diluted
  - EPS: $0.61 per share, basic and diluted
  - Result: reported results
  source text: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update BETHESDA, MD, March 26, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465926035174/0001104659-26-035174-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.